Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Jason Karp Takes Long Position In This Stock, Up By 480% This Year

Page 1 of 2

Jason Karp’s Tourbillon Capital Partners recently filed a 13G form with the SEC indicating that it now owns 7.0% of the common shares of Recro Pharma Inc. (NASDAQ:REPH), 646,552 shares in all. This represents a new position for the hedge fund, as it did not report a stake in the company in its most recent 13F filing.

Jason Karp - Tourbillon Capital Partners

Tourbillon Capital Partners is a fundamentally driven long/short equity hedge fund established by Jason Karp in 2013. The firm employs a low net exposure strategy, implying that its long positions are relatively in balance with its short positions. Tourbillon has $4.53 billion in assets under management, which subsequently categorizes it as a large investment firm with assets above $1 billion, and is led by former SAC Capital Advisors portfolio manager, Jason Karp. Karp has previously worked at SAC’s CR Intrinsic unit as a generalist portfolio manager and director of research during the period of 2005 to 2009. After a relatively quick stop at Carlson Capital, where he served as co-chief investment officer, Karp launched his own shop in 2013 with roughly $250 million under management. Tourbillon’s most recent filing reveals that the fund’s top ten holdings represent 43.83% of its entire portfolio and that its holdings are diversified among the following sectors: 37.80% in the services sector, 19.22% in the technology sector, and 14.31% and 6.45% in the healthcare and consumer/non-cyclical sectors, respectively. The hedge fund manages a public equity portfolio with a value of $3.88 billion as of March 31, 2015.

Jason Karp
Jason Karp
Tourbillon Capital Partners

But why do we track the activity of hedge funds? From one point of view we can argue that hedge funds are consistently underperforming when it comes to net returns over the last three years, when compared to the S&P 500. But that doesn’t mean that we should completely neglect the hedge funds’ activities. There are various reasons behind the low hedge fund returns. Our research indicated that hedge funds’ long positions actually beat the market. In our back-tests covering the 1999-2012 period hedge funds’ top small cap stocks edged the S&P 500 index by double digits annually. The 15 most popular small cap stock picks among hedge funds also bested passive index funds by around 80 percentage points over the 34 month period, beginning in September 2012 (read the details here).

Recro Pharma Inc. (NASDAQ:REPH) is a clinical-stage specialty pharmaceutical company that focuses on developing non-opioid therapeutics for the treatment of pain, initially intended for post-operative pain. As of now, the company has two product candidates in late stage clinical trials for the management of acute post-operative pain. The first product candidate is the recently-acquired IV/IM meloxicam, which is a proprietary, long-acting preferential COX-2 inhibitor that has successfully completed multiple Phase II clinical trials and is ready to begin the vital Phase III clinical trials. The second product candidate is Dex-IN, which is a proprietary intranasal formulation of dexmedetomidine.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!